CD1D and congenital rubella syndrome: ,3 Both systemic activation (using glycolipid Ag- and pAg-based approaches) and adoptive transfer of type 1 NKT and Vγ9Vδ2-T cells were found to have a good safety profile in earlier clinical studies,11,15,22 suggesting a low risk for CRS and/or ICANS upon CD1d-Vδ2 bsTCE infusion.